Kallikrein-related peptidase 2 (KLK2) is a key serine protease involved in the metastatic progression of prostate cancer. The Brandstetter lab now identified that post-translation modification of KLK2 by glycosylation regulates its activation and enzymatic activity. These striking effects of glycosylation pave the way to a deeper understanding of kallikrein-related peptidase function in malignant progression. The study by Shihui Guo et al. has been published in the Journal of Biological Chemistry and can be found here.